Neuro-Oncology: The Podcast

Podcast Host and Interviewee: Shahad Abdulsahib, PhD Candidate, UT Health San Antonio Podcast Description: Shahad Abdulsahib discusses a recent Phase 1 clinical trial on Rhenium-186 nanoliposome therapy for recurrent glioma, published in Nature Communications in March 2025.

Dr. Alex Landry interviews Dr. Gelareh Zadeh on her career in academic neurosurgical oncology, focusing on the role of mentorship, how the field has evolved over time, and advice for junior trainees entering the field.    

Dr. Maya Graham interviews Dr. Lauren Schaff on her manuscript entitled "Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine (R-MVP/i) for newly diagnosed primary CNS lymphoma (PCNSL)," published in Neuro-Oncology in January 2026.

Dr. Nathan Dalton interviews Dr. Joseph Sia on the topic of radiation hypofractionation – its history, current clinical landscape, and potential future developments for patients with gliomas.

Shahad Abdulsahib discusses the findings of a recent paper, entitled " Transcriptional regulation of protein synthesis by mediator kinase represents a therapeutic vulnerability in MYC-driven medulloblastoma ", which was published in Nature Communications in December 2025.

Dr. Rachna Malani interviews Mindy Freund about her work at the American Brain Tumor Association

Dr. Jasmin Jo interviews Dr. Amy Smith and Dr. David Ellison on their manuscript, entitled "Phase 3 randomized trial of post-irradiation chemotherapy in patients with newly diagnosed ependymoma, a report from the Children's Oncology Group" published in Neuro-Oncology in December 2025.

Dr. Dave Rogawski interviews Dr. David Solomon on his research that sheds light on how key genomic alterations in high-grade glioma evolve over time and how these insights might inform therapeutic development.

Dr. Haseeb Mehmood discusses the use of microbubble-enhanced transcranial focused ultrasound combined with standard temozolomide in high-grade glioma.

Dr. Evan Noch interviews Dr. Lisa DeAngelis about her career in neuro-oncology, role as Chair of Neurology and Physician-in-Chief at Memorial Sloan Kettering Cancer Center, and advice for trainees entering the field.

Dr. Iyad Alnahhas interviews Drs. David Schiff and Ranjit Bindra about their recent manuscript entitled "Phase I/II and Window-of-Opportunity Study of Pamiparib and Metronomic Temozolomide for Recurrent IDH Mutant Gliomas", published online in Neuro-Oncology in October 2025.

In this episode, Dr. Evan Noch and Dr. Maya Graham discuss the exciting new podcast subtypes and the episodes to come.

Description: Dr. Iyad Alnahhas interviews Dr. Charlotte Sleurs about her and her team's recent manuscript entitled: "Radiotherapy-induced neurocognitive decline among adult intracranial tumor patients: A voxel-based approach", published online in Neuro-Oncology in May 2025.

Dr. Iyad Alnahhas interviews Drs. Florien Boele and Martin Klein about their recent manuscript entitled: "Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation", published online in Neuro-Oncology in July 2025.

Dr .  Iyad Alnahhas interviews Drs. Felix Sahm and Maximilian Deng about their recent manuscript entitled: "Postoperative radiotherapy in subtotally-resected recurrent WHO grade 1 meningiomas with intermediate/ high-risk molecular profiles", published online in Neuro-Oncology in May 2025.

Dr . Maya Graham interviews  Dr . Jessica Foster about her and her team's recent manuscript, entitled "Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high-grade glioma models". This work was published online in Neuro-Oncology in May 202 5.

Dr. Evan Noch interviews Dr. Akshitkumar Mistry about his and his team's recent manuscript entitled "A clinically annotated transcriptomic atlas of nervous system tumors", published online in Neuro-Oncology in May 2025 Link to the paper: https://academic.oup. com/neuro-oncology/advance- article/doi/10.1093/neuonc/ noaf130/8151442

Dr. Iyad Alnahhas interviews Drs. Isaias Hernandez-Verdin and Agusti Alentorn about their recent manuscript entitled: "Gut microbiome modulates the outcome in primary central nervous system lymphoma patients undergoing chemotherapy: An ancillary study from the BLOCAGE trial", published online in Neuro-Oncology in March 2025   Link:  https://academic.oup. com/neuro-oncology/advance- article/doi/10....

Dr. Evan Noch interviews Dr. Marion Mateos about her and her team's recent manuscript entitled: "Germline analysis of an international cohort of pediatric diffuse midline glioma patients", published online in Neuro-Oncology in March 2025.

Dr. Iyad Alnahhas interviews Drs. Cynthia Hawkins and Arun Vadivel about their recent manuscript entitled: "The proteomic landscape of diffuse midline glioma highlights the therapeutic potential of non-histone protein methyltransferases", published online in Neuro-Oncology in February 2025.   More Information

Dr. Iyad Alnahhas interviews Dr. Peter LaViolette about his and his team's recent manuscript entitled: "Multi-Site Retrospective Analysis of Diffusion and Perfusion MRI Correlates to Glioma Characteristics Derived from Radio-Pathomic Maps", published online in Neuro-Oncology in February 2025.

Description: Dr. Evan Noch interviews Drs. Cecile Riviere-Cazaux and Terry Burns about their recent manuscript entitled: "A field resource for the glioma cerebrospinal fluid proteome: impacts of resection and location on biomarker discovery", published online in Neuro-Oncology in December 2024.   Link:  https://doi.org/10.1093/ neuonc/noae277  

Description: Dr. Ankush Bhatia interviews Drs. Macarena de la Fuente and Mehdi Touat about their recent manuscript entitled: "The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma" published online in Neuro-Oncology in December 2024.   Link:  https://doi.org/10.1093/ neuonc/noae259

Dr. Iyad Alnahhas interviews Dr. Craig Horbinski about his and his team's recent manuscript entitled "The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma", published online in Neuro-Oncology in December 2024.

Dr. Iyad Alnahhas interviews Dr. Nathalie Albert about her and her team's recent manuscript entitled: "Measurable disease as baseline criterion for response in glioblastoma: A comparison of PET-based (PET RANO 1.0) and MRI-based (RANO) assessments", published online in Neuro-Oncology in January 2025.